Genelabs Drug Fails Late-Stage Trial  NEW YORK (Reuters) - Genelabs Technologies Inc. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=GNLB.O target=/stocks/quickinfo/fullquote"&gt;GNLB.O&lt;/A&gt;  said on Tuesday that a late-stage trial of its drug to limit  bone loss in women with lupus disease failed to work.